ArticleeLife2015
Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fcγ receptors.
Article in eLife, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN)
Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Association of Allergic Symptoms with Dengue Infection and Severity: A Systematic Review and Meta-analysis.Virologica Sinica · 2020Pooled it
- Functional antibody responses and protection against symptomatic dengue.Communications medicine · 2026Review
- Anti-DENV IgE correlates with dengue severity and triggers FcεRI-dependent basophil activation inhibited by Omalizumab.Scientific reports · 2026Article
- Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms.Frontiers in immunology · 2026Review
- Role of biomarkers in predicting disease severity in acute dengue and SARs-CoV-2-Infected patients.BMC infectious diseases · 2025Article
- LRO biogenesis and function: what can we learn from mast cells?Frontiers in cell and developmental biology · 2025Review
- Review
- Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19.The Journal of clinical investigation · 2023Article
- Serum biomarkers and anti-flavivirus antibodies at presentation as indicators of severe dengue.PLoS neglected tropical diseases · 2023Article
- Platelet derived exosomes disrupt endothelial cell monolayer integrity and enhance vascular inflammation in dengue patients.Frontiers in immunology · 2023Article
- Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines.Current treatment options in infectious diseases · 2023Review
- Facing the escalating burden of dengue: Challenges and perspectives.PLOS global public health · 2023Review
- Immune-Mediated Pathogenesis in Dengue Virus Infection.Viruses · 2022Review
- Dengue and COVID-19: two sides of the same coin.Journal of biomedical science · 2022Review
- Mast Cells Meet Cytomegalovirus: A New Example of Protective Mast Cell Involvement in an Infectious Disease.Cells · 2022Review
- Article
- Insights into potential causes of vascular hyperpermeability in dengue.PLoS pathogens · 2021Article
- Pathogenesis and virulence of flavivirus infections.Virulence · 2021Review
- Article
- Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation?International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue virus (DENV) is the most significant human arboviral pathogen and causes ∼400 million infections in humans each year. In previous work, we observed that mast cells (MC) mediate vascular leakage during DENV infection in mice and that levels of MC activation are correlated with disease severity in human DENV patients (St John et al., 2013b). A major risk factor for developing severe dengue is secondary infection with a heterologous serotype. The dominant theory explaining increased severity during secondary DENV infection is that cross-reactive but non-neutralizing antibodies promote uptake of virus and allow enhanced replication. Here, we define another mechanism, dependent on FcγR-mediated enhanced degranulation responses by MCs. Antibody-dependent mast cell activation constitutes a novel mechanism to explain enhanced vascular leakage during secondary DENV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.